Navigation Links
PK Plasma V

ProductsPK Plasma V
Company GYRUS ACMI
Item PK Plasma V
Features 
  • Reduced bleeding
  • Improved visualization
  • Limited thermal risk outside the target tissue ( < .5mm spread)
  • IPSS and QMAX improvements equal to or better then monopolar
  • No upper limit to gland size or procedure time
Description PK Plasma V is a single use device that produces rapid, consistent, precise tissue removal with minimal thermal spread and vapor sealing of adjacent tissue for prostatic adenoma in the treatment of BPH, without deep desiccation. Often referred to as PlasmaKinetic vaporization of the prostate (PKVP), the Plasma-V gives the urologist the control needed to achieve the anatomical results desired by urologists.
Info GYRUS ACMI
Customer Service: (508) 804-2600
Web site: http://www.acmicorp.com

Related medicine products :

1. Plasmacup SC
2. Rapid Plasma Reagin (RPR) Sset
3. Macro-Vue RPR (Rapid Plasma Reagin) Control Card
4. Macro-Vue RPR (Rapid Plasma Reagin) Control Cards
5. PK Plasma-CISE/Plasma-CUT
6. Chest-Style Plasma Freezer
7. Upright Plasma Freezer
8. -30 Plasma Freezer
9. Plasma Blast Chest Freezer -50C
10. -40 Plasma Freezer
11. Plasma Blast Upright Freezer -50C
TAG: Plasma
The GC OIA test is a rapid assay for the diagnosis of gonorrhea. Thermo solved the challenge of developing a specific rapid assay for Neisseria gonorrhea by using the proprietary ribosomal protein,
...cceava Group A Strep test delivers excellent sensi...A Strep with a simple, easy-to-use test that provi...s value-added services enable you to provide impro...g requirements of waived laboratories. Find out wh...
Neuroline monopolar needle electrodes are made of PTFE coated stainless steel and feature an ultra-sharp, conical tip, which ensures low friction at the point of insertion. This in turn, provides sig
Shielding's Flex Back Apron is one of our most popular. Similar to the Velcro Adjustable but with elastic back panels for additional support and comfort.
Medicine Products:
(Date:9/5/2008)...s the Latest Developments in Molecular,Testing and... /PRNewswire-USNewswire/ -- The practice of,pathol...g and the promise,of personalized medicine will ch...and other imaging technologies will change the way...ogists is taking a leadership role in,making sure ...
(Date:9/5/2008)...RNewswire-USNewswire/ -- The Health Resources,and ... million in grants to,increase and improve medical... grants continue President Bush,s historic expansi...w reach more economically,vulnerable and geographi...dministrator Elizabeth M. Duke said. "In 2007, mor...
(Date:9/5/2008)...tical ,anti-cloak, could bring objects out of hidi...-- Just in case someone develops a cloak of invisi... how to uncloak the objects it hides. , Accordi...in materials underneath an invisibility cloak woul...esearchers at Shanghai Jiao Tong University in Chi...
(Date:9/5/2008)...ain to commit to develop a National AIDS,Strategy ...p. 5 /PRNewswire-USNewswire/ -- The,Republican Nat...ion of the,domestic AIDS epidemic in the United St...erseas. Neither Presidential nominee Sen. John McC... mentioned AIDS in their remarks,to Convention del...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3
...les, a disease that once infected tens of thousand...s birth defects, is on the verge of being eliminat...len from almost 58,000 in 1969//, the year the vac...ubella, which typically causes a mild rash, was co...
...lder men undergoing coronary artery bypass surgery...e undergoing the procedure.// Coronary artery bypa...f the body to reroute blood around narrowed or clo...uch as fats or plaque causes this narrowing, known...
...ll newborns should be vaccinated against hepatiti... possible disease from infected mothers.Previously... only for newborns// whose mothers were known to b...e new recommendation is listed in the childhood im...
...e of childhood brain cancer has a unique molecule ...best fight it.// Armed with targeted molecular tre...without risking the side effects of prolonged and ... an early age. The latest research is a collaborat...
Other Medicine News:Health News:Babies Need Vaccination 2
(Date:9/4/2008)... Optimizing Patient Identification for Targeted ...sonalized Treatment HUNTINGTON BEACH, Calif., a... Agendia, a world leader in molecular cancer diagn...R), a new diagnostic test that,allows physicians t...els of,the estrogen receptor (ER), progesterone re...
(Date:9/3/2008)...Y, Australia, Sept. 4 /Xinhua-PRNewswire-FirstCall...asdaq: PXSL) today announced,that it has enrolled ...clinical trial evaluating Bronchitol in cystic fib...ucted in 41 hospitals across North,America, Argent...fore,Pharmaxis seeks approval to market Bronchitol...
(Date:9/3/2008)...NG, China, Sept. 3 /- Simce...anufacturer and supplier of,branded generic pharma...ncer biotech product Endu (also known as Endostar)...hase IV clinical study., At the request of the SF... further validate the safety and therapeutic effic...
(Date:9/3/2008)...g term follow up results from chronically infected...positive data obtained earlier in 2008, - Study ...nd long-term antiviral effect of therapeuti...nd strongly support move into a second generation,...1(R) acting through TLR ...
Breaking Medicine Technology:Agendia Launches TargetPrint(R) for Breast Cancer Patients 2Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins 2Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins 3Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Big A Drug Stores Inc Retains DJM Realty to Dispose of All Stores Operating Under the Names of Drug Emporium Big A Camelot Drug Fair and Drug Bar 7371 1Big A Drug Stores Inc Retains DJM Realty to Dispose of All Stores Operating Under the Names of Drug Emporium Big A Camelot Drug Fair and Drug Bar 7371 2How to help baby like fruits and veggies 7368 1How to help baby like fruits and veggies 7368 2WHRC releases 4 key reports 1418 1WHRC releases 4 key reports 1418 2WHRC releases 4 key reports 1418 3WHRC releases 4 key reports 1418 4NEWSWEEK 3A International Editions 3A Highlights and Exclusives December 10 2007 Issue 7364 1NEWSWEEK 3A International Editions 3A Highlights and Exclusives December 10 2007 Issue 7364 2NEWSWEEK 3A International Editions 3A Highlights and Exclusives December 10 2007 Issue 7364 3NEWSWEEK 3A International Editions 3A Highlights and Exclusives December 10 2007 Issue 7364 4NEWSWEEK 3A International Editions 3A Highlights and Exclusives December 10 2007 Issue 7364 5
...NG, Pa., June 25, 2007 /PRNewswire-FirstCall/ --,G...a preclinical,study of trodusquemine (MSI-1436) fo...he American Diabetes Association (ADA) 67th,Scient...ten Lantz,Genaera research scientist and lead aut... is a Multiple Pathway Inhibitor that,Causes Diffe...
...lif.--(BUSINESS WIRE)--Jun 25, 2007 - Gilead,Scien... 103, a,Phase III clinical trial evaluating the co...vir disoproxil fumarate or tenofovir,DF) 300 mg as...us,(HBV) infection, met its primary efficacy endpo...the company,s once-daily antiviral,drug Hepsera(R)...
Other Medicine Technology:Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for,the Treatment of Obesity at the American Diabetes Association 67th,Scientific Session 2Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for,the Treatment of Obesity at the American Diabetes Association 67th,Scientific Session 3Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for,the Treatment of Obesity at the American Diabetes Association 67th,Scientific Session 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 2Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 3Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 6